Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAPIR: Prednisone in Remission for Granulomatosis with Polyangiitis
NCT01933724Phase 3Active, not recruiting
- Sponsor
- University of South Florida
- Start
- Feb 2014
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of prednisone in granulomatosis with polyangiitis (GPA) (2 arms), sponsored by University of South Florida. Primary endpoint: Proportion of participants who increase prednisone for disease relapse at 6 months. Started Feb 2014; status: active, not recruiting.
02
Drugs
prednisone
03
Conditions
granulomatosis with polyangiitis (GPA)
Beyond the preview
Go deeper on NCT01933724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01933724.